BRAIN Biotech AG Financial Results FY 2021 / 22 | Exploring Growth, Challenges, and Future Prospects with CFO

BRAIN Biotech AG FY 2021/22: Key Takeaways Revenue Growth in BRAIN Biotech AG BRAIN Biotech AG, a leading provider of biologization solutions for industries, has reported strong revenue growth in both segments, contributing to a total group revenue increase of 35% and an organic increase of 19% in the first quarter the fiscal year 2022/23.   The BioIndustrial segment saw revenue growth of 43.5%, and the BioScience segment’s revenue increased by 10.5% on an organic basis. The company’s cash on hand also improved by €2.4 million to €10.8 million, including the proceeds from the disposal of L.A. Schmitt GmbH.   Despite higher personnel and project investments, BRAIN Biotech’s adjusted EBITDA remained profitable.   Important events for the quarter included MP Beteiligungs-GmbH expanding its shareholding to approximately 45% and the company reaching project milestones in its collaboration with rare sugars expert Bonumose.   Michael Schneiders, CFO, expressed optimism for the rest of the fiscal year, noting the company’s solid growth as a foundation for handling inflationary costs. BioIndustrial and BioScience Segment PerformanceProfitability and InvestmentsQuarterly Highlights and CollaborationsCFO Insights into Fiscal Year Prospects ================================= ▶️ Other videos:Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ ================================= T&C This publication is for informational purposes only and does not constitute investment advice. By using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.